


MOLECULAR TARGETS AND CANCER THERAPEUTICS

PART 1

Editor:
Faris Q.B. Alenzi

Bentham Books



Molecular Targets and Cancer Therapeutics (Part 1)

Edited by

Faris Q.B. Alenzi

Professor of Immunology

College of Applied Medical Sciences

Prince Sattam Bin Abdulaziz University

Saudi Arabia

Molecular Targets and Cancer Therapeutics (Part 1)

Editor: Faris Q.B. Alenzi

ISBN (Online): 978-981-5080-38-4

ISBN (Print): 978-981-5080-39-1

ISBN (Paperback): 978-981-5080-40-7

© 2023, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2023.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
DEDICATION	ii
LIST OF CONTRIBUTORS	iii
CHAPTER 1 INTRODUCTION	1
<i>Abdulaziz Bin Saeedan, Mohd. Nazam Ansari and Amal Almohisen</i>	
INTRODUCTION	1
Definition	2
Characteristics of Cancer	2
<i>The Hallmarks of Cancer</i>	3
<i>Features of Cancer Cell</i>	4
Epidemiology of Cancer	6
<i>Cancer Epidemiology in the World</i>	7
<i>Cancer Epidemiology in the Kingdom of Saudi Arabia</i>	8
<i>Cancer Registries</i>	9
CONCLUSION	9
CONSENT FOR PUBLICATION	9
CONFLICT OF INTEREST	9
ACKNOWLEDGEMENTS	10
REFERENCES	10
CHAPTER 2 CANCER TRAITS; PRESENT AND FUTURE	12
<i>Khalid A. Asseri and Afaf Ahmed Aldahish</i>	
INTRODUCTION	13
Mechanisms of Contact Inhibition and its Evasion	13
MALIGNANCY SUPPORTED BY THE DEFECTS OF THE TGF-β PATHWAY	15
TUMOR CELL SURVIVAL AND DEATH MEDIATES AUTOPHAGY	19
Tumorigenesis and Tumor Progression Autophagy	20
Autophagy Inhibits Tumor Progression	21
NECROSIS HAS PRO-INFLAMMATORY AND TUMOR-PROMOTING POTENTIAL	22
NECROPTOSIS: A PRO- OR ANTI-INFLAMMATORY MODE OF CELL DEATH	23
NEW FUNCTION OF TELOMERASE	24
Tumorigenesis Due to Malfunction of Telomere	26
Telomeres as Suppressors of Tumors	26
Telomeres as a Potential Target for Therapy	27
THE NEXT GENERATION OF INDUCING ANGIOGENESIS	27
Vascular Endothelial Growth Factor (VEGF) Role in Angiogenesis	29
Cancer Therapy and HIF-1 Inhibitors	30
THE NEXT GENERATION OF ACTIVATING INVASION AND METASTASIS	31
Invasion and Migration	31
Epithelial-to-Mesenchymal Transition (EMT) and Metastasis	33
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells	33
Cancer Cells Promote their Own Growth	35
Abnormalities in the Cell Cycle Control Proteins in Cancer	36
CDK and CDK Activating Enzyme	37
CKI	37
Cell Cycle Control and Cancer Treatment	38
CANCER OPPOSE APOPTOSIS	38
The Extrinsic Pathway	38

The Intrinsic Pathway	39
The Final Pathway: Caspases	40
INHIBITORY SIGNALS THAT MAY GENERALLY STOP CANCER DEVELOPMENT	40
Immune Checkpoint Inhibitors	40
PD-1 Inhibitors	41
CTLA-4 Inhibitors	42
CONCLUSION	42
CONSENT FOR PUBLICATION	45
CONFLICT OF INTEREST	45
ACKNOWLEDGEMENT	45
REFERENCES	45
CHAPTER 3 EXOGENOUS FACTORS AND CANCER	52
<i>Baraa T. Alhajhussein, Majed H. Wakid, Najwa Mohamad Alsawi, Hesham Hamdy</i> <i>Amin and Fahad Nasser Alonazi</i>	
INTRODUCTION	53
BACTERIA AND CANCER	54
Direct Bacterial Carcinogenesis	54
Indirect Bacterial Carcinogenesis	54
Other Roles for Bacteria in Cancer	55
Bacterial Cancer Therapy	57
PARASITES AND CANCER	57
Blood Flukes	58
<i>Mechanism</i>	58
Liver Flukes	60
<i>Mechanism</i>	60
Indirect Carcinogenic Parasites	60
VIRAL ONCOGENESIS	61
Epstein-Barr Virus (EBV)	61
Human Papillomaviruses (HPVs)	62
Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV)	63
Human Immunodeficiency Virus	64
Human Herpes Virus 8 (HHV-8)	64
Human T-Lymphotropic Virus-1 (HTLV-1)	64
Merkel Cell Polyomavirus (MCV)	65
How Viruses Cause Cancer?	65
ROLE OF FREE RADICALS, CHEMICALS IN ONCOGENESIS	65
Sources of Free Radicals	66
<i>Environmental Carcinogens as a Source of Free Radical</i>	67
Development of Cancer and Free Radicals	68
<i>Initial Stage of Tumor Formation and Free Radicals</i>	69
<i>Proliferation of Tumor Cells and Free Radicals</i>	69
<i>Angiogenesis and Free Radicals</i>	70
<i>Metastasis and Free Radicals</i>	70
PHYSICAL ONCOGENIC FACTORS	70
CONCLUSION	71
CONSENT FOR PUBLICATION	72
CONFLICT OF INTEREST	72
ACKNOWLEDGEMENTS	72
REFERENCES	72
CHAPTER 4 BIOLOGY OF CANCER	86

INTRODUCTION	86
CANCER CELLS AND CANCER STEM CELLS	87
INTRODUCTION	87
Cancer and Tumor	87
Cancer Cells	89
Cancer Stem Cells	89
ENDOTHELIAL CELLS	90
INTRODUCTION	90
Angiosarcomas	91
Tumor Endothelial Cells (TECs)	91
Tumor Endothelial Markers (TEMs)	92
Metastasis	93
Cancer Regulatory Systems	93
Angiogenesis	93
PERICYTES	94
INTRODUCTION	94
PCs Origins and Activation	95
PCs Contribution to Tumor Microenvironment and Cross-Talk with Cancer Cells	97
IMMUNE INFLAMMATORY CELLS	97
INTRODUCTION	97
TAMs	98
B Lymphocytes	99
T Lymphocytes	99
Infiltrating Cells	101
<i>Tumor-Infiltrating Lymphocytes (TILs)</i>	102
<i>Myeloid-Derived Suppressor Cells (MDSCs)</i>	102
CANCER-ASSOCIATED FIBROBLAST (CAF)	102
INTRODUCTION	102
CAFs Origins and Activation	104
CAFs Contribution to the Tumor Microenvironment and Cross-Talk with Cancer Cells	105
TUMOR MICROENVIRONMENT (TME)	106
INTRODUCTION	106
Cancer-Non-Cancer Cell Interactions Mechanism	107
Heat Shock Proteins (HSPs)	108
Tumor Microenvironment Alterations at the Histological Level During Carcinogenesis	109
<i>TME at the Early Human Carcinogenesis Stage</i>	109
<i>TME at the Advanced Human Carcinogenesis Stage</i>	110
CONCLUSION	110
GENOMIC INSTABILITY AND MUTATION	110
INTRODUCTION	110
Cell Cycle	111
Regulation of the Cell Cycle	112
Genomic Instability Levels	114
<i>Nucleotide Instability (NIN)</i>	114
<i>Microsatellite Instability (MSI)</i>	114
<i>Chromosomal Instability (CIN)</i>	116
<i>Checkpoints of DNA Damage</i>	117
<i>Mitotic Checkpoints</i>	118
<i>Telomere Maintenance</i>	119
<i>DNA Repair Pathways</i>	120

Conclusion Remarks	124
TUMOR-PROMOTING INFLAMMATION	124
INTRODUCTION	124
“Normal” Inflammation & Inflammatory Response in Tumor and General Mechanisms	126
Inflammation & Tumor Initiation and Progression	128
Involvement of Inflammatory Mediators in Genetic Mutations; Paving the Way for Carcinogenesis	131
CONCLUSION	134
REPROGRAMMING ENERGY METABOLISM	134
INTRODUCTION	134
Glycolysis	137
Krebs Cycle	140
Hexose Monophosphate Shunt (HMS)	141
Lipid Metabolism	144
Amino Acid Metabolism	146
Mitochondria and its Central Role in Carcinogenesis	147
Metabolic Alteration by p53	148
Metabolic Alteration by Kras	148
Concluding Remarks	150
CONCLUSION	150
CONSENT FOR PUBLICATION	150
CONFLICT OF INTEREST	151
ACKNOWLEDGEMENTS	151
REFERENCES	151
CHAPTER 5 GROWTH FACTORS AND CANCER	187
<i>Aisha Al Anazi, Ravi Teja Chitturi Suryaprakash, Kate Shearston and Omar Kujan</i>	
GROWTH FACTOR INDUCED BASEMENT MEMBRANE BREAKDOWN AND INVASION IN CANCER	188
Growth Factor-Induced Basement Membrane Breakdown and Invasive Growth	189
Intravasation	190
Role of Breaching of the Basement Membrane in Tumour Progression	191
The Transforming Growth Factor- β Induced Invasion	193
TGF- β -Induced Epithelial to Mesenchymal Transformation	194
Epigenetic Modification and Basement Membrane Invasion	194
CURRENT UNDERSTANDING OF THE ROLE OF INTRAVASATION, EXTRAVASATION AND DISSEMINATION IN THE DEVELOPMENT OF CANCER	196
Intravasation	196
Macrophage-Assisted Tumour Cell Intravasation	197
Intravasation of Tumour Cells Fusing with Macrophages	197
Intravasation Associated with Trogocytosis	198
Extravasation	198
Tumor Cell Properties Promoting Extravasation	199
Therapeutic Targets: Intravasation and Extravasation	199
Extravasation of Leukocytes and Tumour Cells	200
Dissemination	200
Dissemination of Cancer Cells from a Primary Tumour	202
GROWTH FACTORS INDUCE EVASION FROM CYTOTOXIC THERAPIES: AS TARGETS FOR A NEW STRATEGY IN CANCER TREATMENT	203
Cytotoxic Therapy: An Alternative Approach to Treat Cancer Cells	203
Growth Factor-Mediated Evasion from Cytotoxicity	204

T-Cell-Mediated Cytotoxicity	205
TGF- β and its Role in Tumour Evasion of Immune Surveillance	206
GROWTH FACTORS INDUCE ANGIOGENESIS	207
Mechanism of Angiogenesis in Cancer	208
Vascular Endothelial Growth Factor (VEGF)	209
Fibroblast Growth Factor (FGF)	210
Other Modes of Tumour Vascularization	211
GROWTH FACTORS INVOLVED IN TUMOUR PROGRESSION	212
Platelet-Derived Growth Factor (PDGF) Family	212
Vascular Endothelial Growth Factor (VEGF) Family	213
Neuregulins and the EGF Family	213
<i>Epidermal Growth Factor (EGF)</i>	213
<i>Fibroblast Growth Factor (FGF) Family</i>	214
<i>Hepatocyte Growth Factor (HGF)</i>	214
Transforming Growth Factor- β (TGF- β)	215
Insulin-Like Growth Factor (IGF) Family	215
Neurotrophin Family (NF)	216
CANCER THERAPEUTICS TARGETING GROWTH FACTOR SIGNALING	216
Drugs and Mab that Target Receptors	217
Targeting of VEGF Signalling Pathways	218
Targeting TGF- β Signaling	218
Tyrosine Kinase Inhibitors	218
Ligand Traps of Growth Factors	220
Oligonucleotide-Based Therapeutics	221
CONCLUSION	221
CONSENT FOR PUBLICATION	222
CONFLICT OF INTEREST	222
ACKNOWLEDGEMENTS	222
REFERENCES	222

CHAPTER 6 CELL SIGNALING PATHWAYS IN CANCER 242

Hajir A. Al-Saihati, Mashaal Al-Toub, Hanaa I. Sharaf, Manjari Singh, Mohd. Nazam Ansari and Abdulaziz Bin Saeedan

INTRODUCTION	242
JAK/STAT Signaling Pathway	243
<i>General Features of the JAK/STAT Pathway</i>	243
<i>The Role of the JAK/STAT Pathway in Cancer</i>	245
Notch Signaling Pathway	246
<i>General Features of the Notch Signaling Pathway</i>	246
<i>The Role of the Notch Signaling Pathway in Cancer</i>	247
MAP Kinase, ERK, Ras, and Raf Pathways	248
<i>General Features of the Map Pathway</i>	248
<i>General Features of the ERK Pathway</i>	250
<i>General Features of Ras Signaling Pathway</i>	251
<i>Raf Regulation</i>	252
PI3/AKT Signaling Pathway	253
<i>General Features of the PI3/AKT Signaling Pathway</i>	253
<i>The Role of the PI3/AKT Signaling Pathway in Cancer</i>	254
<i>Association Between PI3/AKT and Different Types of Cancer</i>	254
<i>Treatment for the PI3K/AKT Signaling Pathway</i>	255
Nuclear Factor Kappa B (NF κ B) Signaling Pathway	256

<i>General Features of the NFκB Signaling Pathway</i>	256
<i>The Role of the NFκB Signaling Pathway in Cancer</i>	258
<i>The Role of the NFκB Signaling Pathway in Cancer Therapy</i>	259
Wnt/β-Catenin Signaling Pathway	259
<i>General Features of the Wnt/β-Catenin Signaling Pathway</i>	259
<i>The Role of the Wnt/β-Catenin Pathway in Cancer</i>	261
TGF-β	261
<i>General Features of TGF-β</i>	261
<i>Role of TGF-β in Carcinogenesis</i>	262
CONCLUSION	264
CONSENT FOR PUBLICATION	264
CONFLICT OF INTEREST	264
ACKNOWLEDGEMENTS	264
REFERENCES	264
CHAPTER 7 TRANSCRIPTION FACTORS IN CANCER	273
<i>Rawiah A. Alsiary, Talat Abdullah Albukhari and Waheed A. Filimban</i>	
TRANSCRIPTION FACTORS IN CANCER	273
Signal Transducer and Activator of Transcription (STAT)	275
<i>Definition</i>	275
<i>Types of STATs</i>	275
<i>Features of the STAT Group of Proteins</i>	275
<i>Biochemical Cascade</i>	276
<i>Modes of STAT Activation</i>	276
<i>The Standard Janus Kinase (JAK)-STAT Path</i>	276
Transcriptional Engagement	277
<i>Activation and Functions of STAT Proteins</i>	277
<i>Inactivation of STAT Proteins</i>	279
<i>Mutations Affecting STAT Signaling</i>	279
<i>Cancer & STAT Family Protein</i>	280
<i>STAT Proteins as Targets for Treatment</i>	282
<i>STAT Engagement in Immunotherapy</i>	282
<i>Therapeutic Techniques of Targeting STATs</i>	283
<i>Summary</i>	285
Nuclear Factor-κB (NF-κB) Tumor Transcription Factor	286
<i>Definition of NF-κB</i>	286
NF-κB Subunits	286
NF-κB Signalling Pathway	287
<i>Canonical Pathway</i>	288
<i>Non-Canonical Pathway</i>	289
Role of NF-κB in Cancer	290
Mechanisms Implicated in Tumor Generation	290
NF-κB (Transcription Factor in Tumors)	290
<i>NF-κB as a Transcription Factor</i>	290
<i>NF-κB in Brain Tumors</i>	291
<i>NF-κB Inhibition using Chemical Compounds</i>	291
<i>Activating Mutations of NF-κB Pathway</i>	292
<i>NF-κB and Activin-Induced Colorectal Cancer Migration</i>	292
<i>NF-κB Hyperactivation and Esophageal Squamous Cell Carcinoma</i>	293
Summary	293
WNT (B)-CATENIN SIGNALING	293

Introduction	293
Wnt (β)-Catenin Signalingprotein	294
Wnt/ β -Catenin Signalling Receptor: Frizzled and LRP5/6	295
Wnt/ β -Catenin Signaling Modulators	295
Wnt Signalling Functions in Cancer Progression	295
NOTCH AND HEDGEHOG SIGNALLING PATHWAYS	296
Introduction	296
Notch Signalling Pathway	297
The Components and Process of Notch Signalling Pathways	297
The Hedgehog Signalling Pathway	298
The Components and Process of Hedgehog Signalling Pathway	298
CONCLUSION	301
CONSENT FOR PUBLICATION	301
CONFLICT OF INTEREST	301
ACKNOWLEDGEMENTS	301
REFERENCES	301
CHAPTER 8 EPIGENETIC AND GENETICS FACTORS	320
<i>Abeer A. Alsofyani and Yazan Samih Said</i>	
MOLECULAR MACHINERY FOR METHYLATING DNA	320
MOLECULAR MACHINERY FOR HISTONE MODIFICATION	321
Acetylation of Lysine	321
Methylation of Histone	322
<i>Methylation of Lysine</i>	322
<i>Methylation of Arginine</i>	323
<i>Arginine/Lysine Histone Demethylation</i>	323
<i>Histone Phosphorylation</i>	324
Other Modifications	324
Mechanism of Histone Modifications	324
<i>Direct Structural Perturbation</i>	325
<i>Regulating the Binding of Chromatin Factor</i>	325
<i>Histone Modification Communications</i>	327
CHROMATIN REMODELING COMPLEXES	328
Remodeler Families	328
MICRORNAS	329
AN ANALYSIS OF EPIGENETIC GENE SILENCING IN CANCER	330
Aberrant DNA Methylation in Cancer	330
DNA Hypomethylation	332
DNA Hypermethylation	333
Aberrant Histone Modification in Cancer	335
ROLE OF MICRORNA IN CANCER	338
Inactivation or Amplification of miRNA Genes	338
A Transcriptional Control Mechanism for miRNAs	338
Dysregulated Epigenetic Changes	338
Role of Altered miRNA Expression in Cancer	339
CHROMATIN REMODELING COMPLEXES AND CANCER	339
EPIGENETICALLY SILENCED GENES: THE MOLECULAR ANATOMY	343
ONCOGENIC PRODUCTS DISRUPT THE EPIGENETIC MACHINERY	344
EPIGENETIC THERAPY	345
SUMMARY	346
CONCLUSION	346

CONSENT FOR PUBLICATION	346
CONFLICT OF INTEREST	346
ACKNOWLEDGEMENTS	347
REFERENCES	347
SUBJECT INDEX	589

PREFACE

Oncology is a fast-evolving field. The last decade had witnessed enormous, complex discoveries in cancer biology, genetics, mutations, diagnostics and new targeted biological therapies. The team of expert contributors to this book tried to present these major aspects including, cancer traits, exogenous factors of cancer, the biology of cancer, growth factors of cancer, signaling pathways of cancer and epigenetic factors of cancer, in a simple but, at the same time, using up to date information. The book will be a great resource for medical students, scientists, physicians and other healthcare professionals involved in cancer care and cancer research.

Faris Q.B. Alenzi
Professor of Immunology
College of Applied Medical Sciences
Prince Sattam Bin Abdulaziz University
Saudi Arabia

DEDICATION

I dedicate this book to those who lost their lives because of this disease. May Allah bless them all!

To,

Fatema S. Albady Alanazi

Talal H. Almosaieed Alanazi

Saeed A. Baqader

Abdulla S. Alsiary

Moqaeem A. Alanazi

Nadda F. Alhassainan

Shaikha A. Alhabrdi

Hawazn W. Alnaam

Halah F. Alnaam

Hanan G. Alanazi

Eida S. Alhussani

Fryah A.M. Alshammari

Abdulrahman Zekri

Ghaytha Alshammari

List of Contributors

Abdulaziz Bin Saeedan	College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia
Abeer A. Alsofyani	King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
Afaf Ahmed Aldahish	College of Pharmacy, King Khalid University, Abha, 62529, Asir, Saudi Arabia
Aisha Al Anazi	Department of Paediatrics, Division of Endocrine and Diabetes, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Amal Almohisen	King Saud University, Riyadh, Saudi Arabia
Baraa T. Alhajhussein	King Saud Bin Abdulaziz University for Health Sciences (KSAUHS), Jeddah, Saudi Arabia
Fahad Nasser Alonazi	Saudi Public Health Authority, Riyadh, Saudi Arabia
Hajir A. Al-Saihati	Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al-batin, Hafr Al-batin, Saudi Arabia
Hanadi A. Katouah	Chemistry Department, Faculty of Applied Sciences, Umm Al-Qura University, 21955, Makkah, Saudi Arabia
Hanaa I. Sharaf	Chairperson of Molecular Pathology at King Saud Medical City, Riyadh, Saudi Arabia
Hesham Hamdy Amin	Hotat Bani Tamim General Hospital, Riyadh, Saudi Arabia
Hiba S. Al-Amodi	Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, P.O. Box 715, Makkah 21955, Saudi Arabia
Khalid A. Asseri	College of Pharmacy, King Khalid University, Abha 62529, Asir, Saudi Arabia
Kate Shearston	UWA Dental School, The University of Western Australia, Nedlands, 6009 WA, Australia
Majed H. Wakid	Department of Medical Laboratories Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
Mashaal Al-Toub	Department of Clinical Laboratory Sciences, College of Applied Medical Sciences King Saud University, Riyadh, Saudi Arabia
Manjari Singh	Department of Pharmaceutical Sciences, College of Pharmacy, Assam University, Silchar (Assam), India
Mohd Nazam Ansari	College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia
Najwa Mohamad Alsawi	Alhabib Hospital Group, Riyadh, Saudi Arabia
Omar Kujan	UWA Dental School, The University of Western Australia, Nedlands, 6009 WA, Australia
Rawiah A. Alsiary	King Abdullah International Medical Research Center (KAIMRC), WR King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), P.O. Box 9515, Jeddah, Saudi Arabia

iv

Ravi Teja Chitturi	UWA Dental School, The University of Western Australia, Nedlands, 6009
Suryaprakash	WA, Australia
Talat Abdullah Albukhari	Faculty of Medicine, Um Al Qura University, Makkah, Saudi Arabia
Waheed A. Filimban	Pathology Department, Faculty of Medicine, Um Al Qura University, Makkah, Saudi Arabia
Yazan Samih Said	King Fahad Specialist Hospital, Dammam, Saudi Arabia

CHAPTER 1**Introduction****Abdulaziz Bin Saeedan^{1,*}, Mohd. Nazam Ansari¹ and Amal Almohisen²**¹ College of Pharmacy, Prince Sattam Bin Abdulaziz University, AlKharj, Saudi Arabia² King Saud University, Riyadh, Saudi Arabia

Abstract: Cancer is a complex family of diseases that usually begins with carcinogenesis, in which abnormal cells divide or develop wildly by not following the regular path of cell division and likewise can invade nearby tissues. Cancer cells demonstrate transformations in metabolism, which is frequently more anaerobic than normal and probably can tolerate hypoxic surroundings. The remarkable variability of the disease, at all levels, is the major challenge for cancer medicine. Six biological abilities gained during the multi-stage advances of human tumors are the maintenance of proliferative signaling, the prevention of growth suppressors, cell death resistance, replicative immortality allowance, angiogenesis induction, invasion, and metastasis activation. In this chapter, we discuss the features of cancer cells and the epidemiology of cancer for better understanding.

Keywords: Cancer, Characteristics, Definition, Epidemiology, Features.

INTRODUCTION

The biological revolution of the 20th century completely redesigned all fields of biomedical knowledge, including cancer research. The revolution partially produced by Watson and Crick's finding of the DNA double helix, which began in the mid-century, and continues to this day [1]. Furthermore, understanding its true significance and its long-standing ramifications is still in process. The stream of molecular biology, derived from this finding, provided answers to the most insightful problem of 20th-century biology and described how the genetic structure of a cell or organism determines its outlook and function [2].

Like many other biological disciplines, modern cancer research would have remained a theoretical science if this molecular foundation did not exist. By exploiting the evolution in the sciences of molecular biology and genetics, many

* **Corresponding author Abdulaziz Bin Saeedan:** College of Pharmacy, Prince Sattam Bin Abdulaziz University, AlKharj, Saudi Arabia; E-mail: a.binsaeedan@psau.edu.sa

diverse biological phenomena, including cancer, currently have been partially explained. Surprisingly, it is also seen that most of the perceptions of the origins of malignant disease are out of the laboratory benches of cancer researchers. As a substitute, significant knowledge that drives the need to achieve rapid development in cancer research is delivered from the study of diverse organisms, ranging from yeast to worms to flies [3].

Definition

Cancer is a disease in which an assembly of abnormal cells divides or develops wildly by not following the regular path of cell division and likewise can invade nearby tissues. Persistent subjection of the normal cells to signals that control whether the cell should rest, divide into another cell or die. A degree of autonomy from these signals could result in uncontrolled growth and proliferation develops cancer cells. This could become lethal if this development continues and expands, leading to a major cause of cancer-related deaths owing to the spreading of tumors, and a procedure termed metastasis [4].

The concepts of modern cancer biology are based upon unpretentious principles. Fundamentally, all mammalian cells share analogous molecular networks that control cell proliferation, differentiation, and cell death. Ordinary cells are malformed into cancers as an effect of alterations in these networks at several levels, including the molecular, biochemical, and cellular ones. Such mechanisms for these changes are limited and can be determined.

In the past decade, phenomenal research developments in cancer have given us a perception of how cancer cells progress this autonomy. The present definition of cancer is that it is a disease that involves alterations or mutations in the cell genome. These alterations (DNA mutations) yield proteins that spoil the delicate cellular stability between cell division and quiescence, causing cells that keep multiplying to form cancers [5].

Characteristics of Cancer

Cancer is a complex family of diseases that usually begins with a process called carcinogenesis. Such a complex process involves converting an ordinary cell into a cancer cell in the body. The cancer cells display cellular and nuclear pleomorphic, then lose normal arrangement of cells, therefore developing alterations in the cell membranes and organelles, and hence exhibit abnormal mitoses and chromosomal abnormalities [6].

Intervallic cellular adhesiveness (for the solid surface) and contact inhibition (amid cells) may be the consequences of alterations in the cell surface

glycoproteins and the underdeveloped tight junctions and desmosomes in malignant cells. Fluctuations in motility, adhesiveness, and contact inhibition possibly will promote invasion and the consequent formation of secondary malignant development metastasis.

Compared to a normal cell, cancer cells demonstrate transformations in metabolism. This metabolism of malignant cells is frequently more anaerobic than compared to normal hastily separating cells and is immensely speeded. Malignant cells can probably tolerate hypoxic surroundings. Glucose and amino acid uptake might be greater than before. These cells have extraordinary levels of hexokinase accumulation in their glucose consumption. In this scenario, the cancer cells lose the ability to synthesize specialized proteins distinct from segregated cells. Tumor growth is based on enzymes and other proteins produced by cancer cells [6].

The Hallmarks of Cancer

The remarkable variability of the disease at all levels, is the major challenge for cancer medicine. In the fall of 1999, Robert A. Weinberg and Hanahan depicted there were no credible organizational rules for the biological characteristics of tumors. In January 2000, they published an article “The Hallmarks of Cancer” to summarize these rules. The hallmarks of cancer constitute a fundamental belief that may deliver a rational basis for refining this complexity to better understand the mechanisms of the disease in its various manifestations [7].

For rationalizing the dynamics of neoplastic disorder, the hallmarks represent an organizing concept. Six biological abilities gained during the multi-stage advances of human tumors are the hallmarks of cancer. They comprise the maintenance of proliferative signaling, the prevention of growth suppressors, cell death resistance, replicative immortality allowance, angiogenesis induction, invasion, and metastasis activation. Underlying these hallmarks is genome instability, which produces the genetic variation which fast-tracks their acquisition, and inflammation, which nurtures several hallmark roles. Former era, conceptual advancement has added two emerging hallmarks of future generality to this list: energy metabolism reprogramming and evading immune destruction [7]. Apart from cancer, cell tumors demonstrate another measurement of complexity: they include a repertoire of engaged, ostensibly normal cells that contribute to the acquisition of hallmark characteristics by creating the “tumor microenvironment”. Increasingly, awareness of the extensive application of these ideas will inspire the creation of innovative ways of treating human cancer.

The conceptualization includes eight acquired abilities-cancer hallmarks, and two generic neoplastic disease characteristics that promote their acquisition during the multi-stage neoplastic growth and malignant progression phase. Numerous cell

Cancer Traits; Present and Future

Khalid A. Asseri^{1,*} and Afaf Ahmed Aldahish²

¹ College of Pharmacy, King Khalid University, Abha 62529, Asir, Saudi Arabia

² Pharmacology & Toxicology Department, College of Pharmacy, King Khalid University, Abha 62529, Asir, Saudi Arabia

Abstract: This chapter on “Cancer Traits; Present and Future” begins with a description of the process of carcinogenesis and, finally, the abnormal process leading to carcinogenesis.

Cancer is a multi-step mechanism in which cells undergo biochemical and behavioral changes, causing them to proliferate in an unnecessary and untimely manner. These changes occur from modifications in mechanisms that regulate cell proliferation and longevity, relationships with neighboring cells, and the ability to escape the immune system. Modifications that contribute to cancer require genetic modifications that alter the DNA sequence. Another way to alter the program of cells is to adjust the conformation of chromatin, the matrix that bundles up DNA and controls its access through DNA reading, copying and repair machinery. These modifications are called “epigenetic. The abnormal process that leads to carcinogenesis includes early mutational events in carcinogenesis, microRNAs in human cancer and cancer stem cell hypothesis, Contact inhibition of proliferation, autophagy, necroptosis, signaling pathways, telomere deregulation, microenvironment, growth suppressors evasion, resisting cell death and sustained cell survival, enabling replicative immortality through activation of telomeres, inducing angiogenesis, ability to oppose apoptosis, and activating invasion and metastasis. Intensive research efforts during the last several decades have increased our understanding of carcinogenesis and have identified a genetic basis for the multi-step process of cancer development. Recognition and understating of the prevalent applicability of cancer cell characterization will increasingly affect the development of new means to treat human cancer.

Keywords: Angiogenesis, Apoptosis, Metastasis, Proliferation, Telomerase.

* Corresponding author Khalid A. Asseri: Pharmacology & Toxicology Department, College of Pharmacy, King Khalid University, Abha 62529, Asir, Saudi Arabia; E-mail: kaasseri@kku.edu.sa

INTRODUCTION

Mechanisms of Contact Inhibition and its Evasion

The term 'contact inhibition' denotes two separate but carefully related processes in cell biology, proliferation contact inhibition and locomotive contact inhibition, established by fibroblasts while in connection with each other. Fibroblasts, until they come into contact with a neighboring cell, they move about the culture dish surface. It leads to the inhibition of further cell migration, and regular cells attach each other, making a collection of cells on the culture dish. Around the surface of the culture dish, standard fibroblasts travel until they meet a neighboring cell. Regular cells bind to each other, and further cell migration is inhibited [1].

The elementary property (Contact inhibition of Proliferation (CIP)), by which cells stop to multiply and differentiate as allotted space is filled at the confluence point. CIP is upturned under conditions including augmented cell growth and proliferation, such as healing wounds or tissue regeneration and development of the embryo. However, CIP is absent in cancer cells, and the absence of this factor leads to tumorigenesis [2].

CIP is a regulatory process that helps prevent cells from expanding into a single cell layer of thickness. If the usable substrate space in the cell is more, it duplicates easily and travels liberally. This process will last until the cells surmount the entire substratum. Regular cells would avoid replicating at this stage. When motile cells come across the confluent cultures, they display diminished mitotic activity and mobility over time. Further, though mitotic inhibition occurs later, the ascending growth occurs between colonies in contact for several days. This delay between cell interaction and the initiation of inhibition of proliferation decreases as the culture becomes more mingled. Therefore, cell-cell contact is a necessary prerequisite for preventing the spread of contact but for mitotic inhibition, it is inadequate. In addition to interaction with further cells, under the restrictions and mechanical tension exerted by neighboring cells, the cell area of the contact-inhibited cell, reduces. Mechanical stress has also been proposed to serve as an inhibitory indication for mitosis. Also, mitotic inhibition is a spatial phenomenon that happens among a small number of cells in a potentially diverse population [3].

Unchanged human cells display natural cell activity and mediate their development and spread through interactions between signaling of growth factor, cell density and environmental nutrients. As cell density rises and uniform culture is formed, cell cycle arrest is activated, and mitogen signaling pathways are regulated independently of cell metabolism or external factors. This effect is known as CIP and is important for the suitable development of the embryo as well

as for differentiation, morphogenesis and tissue recovery; CIP is one of the main deregulation mechanisms in transformed cells during tumorigenesis. Many cancer cells are unaffected by confluence-tempted proliferation. Several theories were suggested to clarify the beginning of contact-reliant development arrest, like the discharge of inhibitory composites, the part of cell form on nutritional fatigue or growth aspects or growth or in the culture medium. This results in the migration of adjacent tissues, their metastases to adjacent organs, and ultimately tumorigenesis [1].

Cell-cell interactions influence intracellular signaling trails, such as ERK and Akt, and cell cycle growth is inhibited. To receptors that ease cell bonds, such as E/VE-Cadherin, growth factor receptors, interact themselves. Also, by automatically bonding adjacent cells and disturbing the spreading of traction powers, cadherins avoid interaction in multicellular clusters. Family proteins of ERM, Atypical Cadherin, Fat and Merlin, are also a part of the Hippo pathway that has developed as unique key regulators for the determination of organ size in both mammalian systems and drosophila, and contact inhibition. The lack of immunity related to malignant cell contact suppression will be affected by a reduction in the bond between the disk surface and malignant cells. Also, it could be from a rise in adhesion amid the regular and malignant cells, representing the *vitro* substitute as contact inhibition to the method to keep normal tissue homeostasis *in vivo*. When faced with normal cells, the movement of malignant cells in a given direction is not inhibited. The passage of regular cells, on the other hand, is obstructed when it is met by cells of malignancy. The cells are more rounded and extended than the malignant ones, which are spindle-made. Rounding of the cell is perhaps the index of the cell absence of adhesion to the substrate. Gene activation is caused by Cell-cell contact [1].

Recently, the NF2 gene product has been recognized by Merlin that it is involved in the suppression of the binding of adhesion molecules to the tyrosine kinase transmembrane receptor. The adhesivity of Merlin improves Cadherin-linked cell-to-cell bonding, and by recapturing receptors of growth factors, its ability to produce mitogenic signals is condensed. The other way of inhibition includes the epithelial polarity protein (LKB1), which escapes the mitogenic properties of enhanced Myc oncogene in ordered epithelial structures; on the other side, when expression LKB1 is inhibited, epithelial reliability is weakened, leading to Myc-induced renovation.

Cell adhesion affects a variety of cell behaviors by providing a wide range of mechanical and biochemical signals for cells. The Hippo-YAP pathway, which is primarily responsible for hindering cell formation in mammals, is one such pathway. Mainly, this pathway consists of a phosphorylation cascade, which is

Exogenous Factors and Cancer

Baraa T. Alhajhussein^{1,*}, Majed H. Wakid², Najwa Mohamad Alsawi³,
Hesham Hamdy Amin^{3,4} and Fahad Nasser Alonazi⁵

¹ King Saud Bin Abdulaziz University for Health Sciences (KSAUHS), Jeddah, Saudi Arabia

² Department of Medical Laboratories Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia

³ Hotat Bani Tamim General Hospital, Riyadh, Saudi Arabia

⁴ Al Azhar Faculty of Medicine, Egypt

⁵ Saudi Public Health Authority, Riyadh, Saudi Arabia

Abstract: The causation of cancer, whether exogenous or endogenous, is a cornerstone of cancer prevention and treatment. Many intrinsic factors are discussed in other chapters of this book; this chapter will shed light on exogenous factors influencing cancer with detailed specific examples of microbial, physical and chemical factors.

Microbial role in cancer has been debated over many centuries, whether as an antagonist or a cause, since Imhotep's time through the mid-17th century when cancer was considered contagious, and later cancer hospitals were forcefully moved out of the cities as isolation camps. There are now vivid evidences that specific microbial pathogens are causing up to 25% of cancer cases (lymphoma, solid or others), and in some cases, a single pathogen was found in association with many types of cancer, such as HPV and EBV, to a lesser extent.

Also, several non-biological factors are classified as carcinogens as humans are exposed to millions of chemicals whether in environment or smoke processed food.

Keywords: Bacterial carcinogen, Free Radicals, Microbial carcinogenesis, Parasitic carcinogen, Radioactive cancer, Smoke and cancer, Viral carcinogen.

* Corresponding author Baraa T. Alhajhussein: King Saud Bin Abdulaziz University for Health Sciences (KSAUHS), Jeddah, Saudi Arabia; E-mail: alhajhusseinbt@gmail.com

INTRODUCTION

Since cancer was first described as a human disease in 2600 BC., microbes were thought to play a role in cancer but rather as an antagonist than a cause. This was reflected by the practice of the Egyptian physician Imhotep who would incise the area of tumor to infect such location so that infection, would cause tumor regression [1].

Centuries later, Zacutus Lusitani and Nicholas Tulp promoted the contagion theory in 1649 and 1652, respectively, concluding that cancer was contagious based on their experiences with breast cancer in members of the same household in the Netherlands. They further proposed patient isolation, that has been officially adopted later in France in 1779 when cancer hospitals were moved by force out of the cities as the public belief was that cancer is contagious [2, 3].

In addition to many theories attributing cancer to intrinsic factors discussed in the other chapters of this book, the role of exogenous causes of cancer was still active. In 1921, after discovering the active cancer-causing agents (carcinogens) in cigarette smoke, the Institute of Cancer Research assigned Sir Ernest Kennaway to investigate the carcinogenic properties of tars and oils [4].

Only a few years after describing Burkitt lymphoma in 1958, it was the first time ever to associate a specific microbe with human cancer when Burkitt lymphoma was linked to Epstein-Barr virus (EBV) in 1964 [5]. In 1980s, human papillomavirus DNA of HPV types 16 and 18 were linked to cervical carcinogenesis after being identified in a high proportion of cervical cancer biopsies [6], and soon after, other types of cancer were identified in association with HPV [7].

On the other hand, a century after the first successful surgical treatment of gastric cancer in 1881, *C. pyloridis* (later named *H. pylori*) has been proved to be causing gastric ulcer in 1983 [8] and soon after a cause of gastric cancer [9].

As humans and other living beings have potential exposure to millions of environmental chemicals worldwide, controlling inflammation and its resolution will be a critical component of successful cancer prevention and treatment of cancer [10]. Epidemiological studies guided the resolution of the World Health Organization's International Agency for Research on Cancer to classify processed meat as a group I carcinogen of which the risk category is similar to that of alcohol and cigarettes [11]. Currently, around 25% of human cancers are associated with infectious diseases, of which some have been confirmed as the cause [12].

BACTERIA AND CANCER

Although microbial infections have been associated with cancer for centuries but not specifically among the leading causes of cancer. However, nominating *H. pylori* as the first bacteria to be identified as a cause of human cancer in humans, followed by the discovery of its inflammatory mechanism of carcinogenesis in the early 1990s, by which bacteria cause cancer made the proof of causation [13]. *Chlamydomphila pneumoniae* is an intracellular Gram-negative bacillus that has been detected in a number of chronic lung diseases, most commonly in adults. However, there is more evidence that links *C. pneumoniae* infection and lung carcinomas, especially in heavy smokers [14]. In addition, studies on survivors of colorectal cancer (CRC) have concluded the causative role of *Streptococcus bovis* in colon malignancy where *S. bovis* bacteremia was the strongest signal [15].

Direct Bacterial Carcinogenesis

Microbial Carcinogenesis is a multistep process orchestrated by both host genetic and epigenetic changes in either the oncogenes, tumor suppressor genes or different molecules involved in cell adhesion in addition to microbial toxins or metabolites that also modulate host cell transformation [16].

This is reflected classically in *H. pylori* infection, where the bacteria release reactive nitrogen species (RNS) and reactive oxygen species (ROS), where both strongly trigger “stem cell” hyperplasia followed by increased telomerase activity and, therefore, telomere reduction in parallel with overexpression of hTERT. Consequently, DNA replication errors, DNA hypermethylation, and p53 mutations, along with CD44 abnormal transcripts composing the early steps of well-differentiated gastric cancer [17].

In addition, the risk is considerably driven by *H. pylori* strain virulence variation exacerbated by the host immunogenetics governing the resulting inflammatory response. Such interactions can directly cause specific tissue damage, leading to gastric cancer development [18]. Because of underreporting tumor-associated clinical symptoms prior to diagnosing the disease, nearly half of cases end up being advanced complicated type gastric cancer upon the first visit and therefore, the prognosis is poor [19].

Indirect Bacterial Carcinogenesis

The second bacterial oncogenesis mechanism is driven by the oncogenic metabolites of bacteria. The best example is the microbiota-associated colon

Biology of Cancer

Rawiah A. Alsiary^{1,*}, Hanadi A. Katouah², Hiba S. Al-Amodi³ and Mashael Al-Toub⁴

¹ King Abdullah International Medical Research Center (KAIMRC), WR King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), P.O. Box 9515, Jeddah, Saudi Arabia

² Chemistry Department, Faculty of Applied Sciences, Umm Al-Qura University, Makkah, Saudi Arabia

³ Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, P.O. Box 715, Makkah, Saudi Arabia

⁴ Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia

Abstract: Loss of genomic stability in the cell due to defects in the checkpoint of DNA damage, mitotic checkpoint, and telomere maintenance led to increased incidences of base pair alterations. Therefore, that genomic instability plays a critical role in tumor initiation and progression. Tumor progression requires a dynamic tumor/normal exchange in their microenvironment to support tumor growth. The histological alteration seen in the tumor at early stages confirms that the surface between the epithelium and the stroma undergoes progressive disturbance. Tumor progression is also affected by the immune system in which chronic inflammations promote the growth of tumor. Tumor cells experience altered metabolic profiling to support their growth. Cancer cells are characterized by uncontrolled cell division. For that, they utilize glucose as a source of energy to help them grow faster than normal cells. Hence, Glycolysis is a key metabolomics pathway consumed at a high rate during carcinogenesis.

Keywords: Cancer Biology, Cancer Cell Metabolism, Cell Cycle, Pericytes, TME.

INTRODUCTION

Stem cells are distinguished by their ability to continue to grow and differentiate into various cell types. In this chapter, we'll glance at the most common types of cells in the human body. The body's cells go through a constant cycle of renewal,

* **Corresponding author Rawiah A. Alsiary:** King Abdullah International Medical Research Center (KAIMRC), WR King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), P.O. Box 9515, Jeddah, Saudi Arabia; E-mail: alsiaryra@ngha.med.sa

aging, and eventually death. Endothelial cells, for example, are renewed every 150 days in adults. Mutations disturb this cycle in some cases, causing an abnormal accumulation of defects in the tissues, which finally leads to the formation of cancer cells. The cancer spreads uncontrollably and is linked to cell mass, which is influenced by a variety of factors, including blood supply, extracellular matrix, and cell-cell interactions, as well as changes in oncogenes and tumor suppressor genes. Endothelial cells are important in the function of blood vessels, including angiogenesis. As a result, endothelial cell defects may contribute to tumor development. As endothelial cells line the inside of the vessel wall, pericytes cover the surface of the vascular tube and sustain the tumor microenvironment and cross-talk with cancer cells.

CANCER CELLS AND CANCER STEM CELLS

INTRODUCTION

In the human body, stem cells can differentiate into different cell types. They are characterized by a continuation of development, differentiation and tissue repair. There is a relationship between stem cells and cancer cells; they share the self-renewal property, which is a highly essential characteristic. Indeed, stem cells are affected by mutations that cause the accumulation of cancer and produce cancer cells [1].

Several studies have reported that the cells in the body are in a continuous cycle of renewal, aging and then dying. In fact, this cycle is disrupted in some conditions by mutations to the deoxyribonucleic acid (DNA) and causes abnormal accumulation of tissues and different types of cancer cells, including cancer stem cells (CSCs), which are generated from stem cells. Therefore, both stem cells and cancer stem cells show a critical role in the initiation and progression of cancer (Fig. 4.1) [2]. Furthermore, there are always changes in the mechanism of cancer due to cancer proliferation. In fact, cancer development is uncontrolled and has a relationship with cell mass, which depends on many factors such as blood supply, extracellular matrix, cell contacts, differentiation, immune attack and cell death. In addition, cancer development is dependent on any changes to the cancer regulatory systems, which are oncogenes and tumor suppressor genes [3].

Cancer and Tumor

There is a misunderstanding between the definition of cancer, tumor and neoplasm. The following explanation is to clarify the meaning and the difference between them. Cancer is an abnormal progression of cells, which divide uncontrollably anywhere in the body tissues and invade neighboring tissues [4, 5].

Indeed, the actions of cancer are changeable during cancer development. Thus, the process involved in the formation of cancer is the multi-pathway mechanism called carcinogenesis [6].

However, cancer is illustrated by oncogenic mutations in a target cell or appears after several years [1]. In fact, the breast, lung, bone marrow, gut and prostate tissues contain stem cells that play an important role in cancer development [1]. Moreover, there are different types of cancers, such as carcinoma, leukemia, lymphoma, melanoma and sarcoma. The main diagnosed type is carcinoma, which is a cancer of many organs and glands, such as the breast, lungs, pancreas and skin. Furthermore, the cancer of the blood is called leukemia. In addition, the cancer of lymphocytes is lymphomas, and the cancer of melanocytes is melanoma. However, the rarest type of cancer is sarcoma, which starts in the bones and in the soft connective tissues, such as tendons of the arms or legs [4].




Fig. (4.1). Generation of cancer stem cells (CSCs) from stem cells and progenitor cells and formation of cancer [4].

A tumor is not certainly cancer. Moreover, a tumor is an uncontrolled development of cells without inflammation in the body tissues. In addition, the body does not need them, and they don't die [5]. However, the origination of the tumor is from the transformation of normal stem cells [7]. Furthermore, a tumor can be benign or malignant. Also, a collection of pus can be a tumor [5]. Indeed, tumors heterogeneity plays an important role in cancer cell types [8].

On the other hand, neoplasms are defined as the innovative growth independent from the nature of that growth [6].

CHAPTER 5**Growth Factors and Cancer****Aisha Al Anazi^{1,*}, Ravi Teja Chitturi Suryaprakash², Kate Shearston² and Omar Kujan²**¹ *Department of Paediatrics, Division of Endocrine and Diabetes, Prince Sultan Military Medical City, Riyadh, Saudi Arabia*² *UWA Dental School, The University of Western Australia, Nedlands, 6009 WA, Australia*

Abstract: Cancer causes major patient morbidity and mortality and is a critical health concern worldwide. The recent GLOBOCAN 2019 factsheet recorded nearly 19.2 million new cancer cases, 9.9 million cancer deaths and 50.55 million people suffering from different kinds of cancer globally within 5 years after diagnosis. Growth factors (GF) are a group of proteins that can affect cellular processes, including differentiation, division, intravasation, extravasation and dissemination. The circulating tumor cells in the bloodstream can populate distant tissues and organs and believe to be the primary cause of metastasis. Extravasation is a crucial phase in the metastasis process, in which tumor cells leave the bloodstream and enter the host tissue. The progress of metastasis is triggered by the tendency of cancer cells to disseminate to target organs from the site of the primary tumor. Despite extensive basic scientific and clinical investigations, cancer is still a major clinical and public health problem. The development of cancer can be influenced by genetics, environmental factors, gene-environment interaction, lifestyle, age and a number of other factors. The harnessing and enhancement of the body's own cytotoxic cells to prevent basement membrane rupture and the intervening dissemination processes can provide useful insight into the development of cancer. The mutation in oncogenes and tumour suppressor genes, and chromosomal aberration is a cornerstones of the molecular basis of cancer. The basement Membrane (BM) acts as a cell invasion shield, thus identification of processes that underlie in breaching of BM can contribute to understanding the disease pathogenesis. TGF- β is known for its dual function; it requires inhibition in the advanced stage however, the growth inhibitory properties are displayed in the early stages of tumorigenesis. Therefore, inhibition of TGF- β signalling in the CD8+ T cell compartment may be necessary for tumor immunity to be restored. Quantitation of tumour cell dissemination is important and plays significant role in elucidating mechanisms of cancer and strategies for therapeutic intervention.

Keywords: Cancer, Growth Factors, Oncogenesis, Tyrosine Kinase Inhibitors.

* **Corresponding author Aisha Al Anazi:** Department of Paediatrics, Division of Endocrine and Diabetes, Prince Sultan Military Medical City, Riyadh, Saudi Arabia; Email: dr_aisha2005@hotmail.com

GROWTH FACTOR INDUCED BASEMENT MEMBRANE BREAKDOWN AND INVASION IN CANCER

Cancer, which causes major patient morbidity and mortality, is a critical health concern worldwide. Metastasis is a multistep process caused by tumor growth, angiogenesis, detachment of tumor cells, and invasion of the extracellular matrix that can lead to uncontrolled growth potential and metastasis into surrounding tissues [1]. Each of these steps is critical for the survival of tumor cells and the development of secondary lesions. Interactions between tumor cells and the host microenvironment influence tumor survival and development. Tumor invasion involves the disruption of the basement membrane and infiltration of the underlying stroma. Invasion necessitates significant changes in cell morphology and phenotype, especially in epithelial cells, which are the precursors of more than 90% of human cancers. It includes adhesion between cell-cell and cell-matrix could be responsible for the degradation of the matrix and cellular motility [2].

Tumor development is only permitted after the dissolution of the decorating secretory ducts of the basement membrane. Growth factors play a crucial role in the destruction of the basement membrane, the intrusion into adjacent tissues by cancer cells, the vascular or lymphatic networks (intravasation), as well as exit from the bloodstream (extravasation) and eventual invasion of distant organs [3]. In experimental data conducted on clinical specimens and ErbB-2/HER2-overexpression, spheroids resembling mammary ductal carcinoma *in situ* (DCIS) raised the likelihood that invasive growth was underpinned by TGF- β or 14-3-3-zeta adaptor overexpression [4, 5]. In *in vitro* models, TGF- β and other growth factors seem to have been involved in certain transformations. GFs have been shown to cause multiple adhesion molecular switches, such as a loss of epithelial E-cadherin and a gain of mesenchymal N-cadherin [6]. Tensin-3 is a connective protein that links the actin cytoskeleton and the extracellular matrix, which is replaced by tensin-4, resulting in the disruption of the bridge and facilitating cell migration [7]. In certain epithelial tumours, E-cadherin's growth arrest and adhesive functions are lost by mutational inactivation, transcriptional suppression, or extracellular cadherin domain proteolysis. A number of GFs, which include TGF- β , EGF, and Notch cleaved proteins, affect the expression of repressors of E-cadherin. Further, E-cadherin cleavage, ubiquitylation, and endocytosis may cause E-cadherin downregulation [8].

The degree and timing of invasion and metastasis may be affected by several factors, including genetic and epigenetic heterogeneity within the tumor, extrinsic factors and growth factors [9]. Growth factors and cytokines produced by the tumour microenvironment and tumour cells themselves, are the key extracellular triggers that control these migration programs and, thus, regulate strategies for

adaptive invasion. They can work in an autocrine, paracrine or endocrine manner to orchestrate central cell functions, including proliferation, differentiation, apoptosis and cell migration [10]. Metastases are a major reason for the failure of modern cancer therapies and associated mortality and are caused by the detachment of malignant cells from the primary tumor site and colonisation of close and remote organ sites. Precise knowledge of the molecular mechanisms regulating each step of metastasis is required to understand the pathophysiology of cancer. Cancer metastasis is a multi-step process that comprises local invasion, neoangiogenesis, circulatory system survival, extravasation to the target organ, and so on. Tumor cells must remodel, or lose their basement barrier, in order to reach vessels and get access to distant organs [11]. Research so far has strongly suggested that the basement membrane acts as a cell invasion shield, therefore investigations into basement membrane invasion can provide useful insight into the development of cancer.

Growth Factor-Induced Basement Membrane Breakdown and Invasive Growth

Growth factors are small polypeptides that bind to kinase-activating transmembrane receptors to activate a certain set of intracellular signaling pathways. Examples include mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), phospholipase C- γ , and transcription factors, such as STATs or SMAD proteins [12, 13]. Growth factors encourage cell growth and proliferation, and are considered the main growth regulatory molecules for cells *in vitro* culture and likely *in vivo*. In culture conditions, non-transformed cells display an absolute necessity of growth factors for proliferation. And in most cases, more than one factor is needed. Growth factors are exhausted more quickly than other media components under standard culture conditions and hence rate limiting for proliferation. In neoplastic transformed cells, there is commonly a lack or reduced requirement for specific growth factors, which is the hall mark of cancer cells [12, 14]. The accumulation of genetic changes and genomic instability leads to tumorigenesis. Genomic instability describes a genome containing variation in a genetic sequence that may affect gene expression, and protein expression, known as mutation. It also includes epigenetic and chromosomal alteration [14]. Genomic instability is considered the cornerstone of the molecular classification of cancer. The most prevalent form of genomic instability is chromosomal instability, and the presence of a high degree of chromosome structural modifications has been reported in tumour cells [15]. A driver mutation is an alteration that gives cancer cells a selective advantage compared to other cells, leading to cell proliferation and tumor growth [16]. Previous studies suggested the role of GFs in the step-wise progression of cancers.

Cell Signaling Pathways in Cancer

Hajir A. Al-Saihati^{1,*}, Mashaal Al-Toub², Hanaa I. Sharaf³, Manjari Singh⁴, Mohd. Nazam Ansari⁵ and Abdulaziz Bin Saeedan⁵

¹ Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al-Batin, Hafr Al-Batin, Saudi Arabia

² Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia

³ King Saud Medical City, Riyadh, Saudi Arabia

⁴ Department of Pharmaceutical Sciences, College of Pharmacy, Assam University, Silchar (Assam), India

⁵ College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia

Abstract: Cancer is characterized by atypical cell proliferation that has the possibility of dissemination to different body parts. Tumor formation is influenced by genetic mutations and environmental pollutants. The formation and progression of malignancies have been linked to a diversity of molecular paths. The JAK/STAT, NOTCH, PI3K/AKT pathway, mitogen-activated protein kinase (MAPK), transforming growth factor-beta (TGF-beta) (TGF-), NF-B, and Wnt signaling pathways will be highlighted in this chapter. Cancer development has been linked to various changes to the signaling pathways' components. As a result, various initiatives to target signaling pathways in order to build distinct treatment lines have been approved. In this chapter, we discuss the role of signal transduction in cancer-associated processes and how their targets influence the behavior of the tumor cells.

Keywords: Cancer, JAK/STAT, Map Kinase/Erk, NFκB, Notch, PI3K/AKT/mTOR, TGF-β, Wnt/β catenin.

INTRODUCTION

Malignance is a widespread disease described by genetic modifications in signaling pathways, for instance, cell division, death, and proliferation. Mutations in proto-oncogenes can alter cell formation and homeostasis by regulating signaling pathways such as NFB, TGF-β, PI3K/AKT/mTOR, MAP Kinase/ERK,

* Corresponding author Hajir A Al-Saihati: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al-Batin, Hafr Al-Batin, Saudi Arabia; E-mail: hajirsh@uhb.edu.sa

Notch, JAK/STAT, and Wnt/catenin. These pathways will give crucial information for the proper identification of cancer biomarkers in the future, which will aid in the treatment and prevention of cancer. During cancer formation, genetic and epigenetic changes cause cells to break free from homeostatic control, multiply, expand, and spread to other organs [1].

Liver, Lung, breast, skin, and pancreatic cancers arise in epithelial cells. Sarcomas in fibroblasts, myocytes, adipocytes, and osteoblasts are thought to originate in the mesenchymal tissues. Non-epithelial tumors, on the other hand, develop in nervous system cells such as glioma cells and hematopoietic tissues such as leukemia and lymphoma [2]. In solid tumors, such cellular changes drive the evolution of benign tumors into proliferative malignancies [1]. The tumor cell loses access to oxygen and other nutrients during tumor excursion, causing the development of angiogenesis, which restores cell's access to oxygen and nutrients [3]. Consequently, the tumor cells gain the potential to travel beyond their normal bounds to surrounding organs, enter circulation, and start metastasis, indicating that the tumor is malignant [4].

This design illustrates how complicated cancer-related events occur in a linear sequence in a varied manner in which cancers differ from one another and between tumour locations. This sequence also offers a useful foundation for various signaling pathways tangled during cancer onset and course [5]. The major reason for malignancy, as stated above, is epigenetics or genetic abnormalities in tumor cells. Tumor cells also have a variety of distinct characteristics. These factors include resistance to apoptosis and other kinds of cell death, metabolic changes, genetic instability, angiogenesis activation, and other factors with greater travelling potential, in addition to cell proliferation [6]. The majority of these features are caused by the dysregulation of various cellular signal transduction pathways [7, 8].

JAK/STAT Signaling Pathway

General Features of the JAK/STAT Pathway

JAK-STAT signaling pathways are based on traditional signaling models in which a ligand binds to the transmembrane receptor's extracellular side and initiates a cascade of phosphorylation events [9]. Phosphorylation of JAK kinases, the receptor cytoplasmic tail and STAT transcription factors are among these processes. STAT phosphorylation leads to nuclear localization, DNA binding, and gene regulation [10]. Combining a variety of ligands and receptors with four JAK proteins (JAK1, TYK2, JAK2 and JAK3), 7STAT members (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6) are cytokine signaling

suppressors. Proteins (SOCS), and multiple STAT-dependent operons allow for fine control of expression (Fig. 6.1) [11].




Fig. (6.1). JAK/STAT signaling pathway. The JAK/STAT signaling pathway is a signaling system that involves the proteins JAK and STAT proteins. JAK is phosphorylated by cytokines and growth receptors, and it recruits signal transducers and transcription activators (STAT). Dimer phosphorylated STAT enters the nucleus and stimulates gene transcription, where it attaches to DNA, regulates immunity, and promotes cell growth and survival.

JH1 encompasses the kinase domain, JH2 encompasses the inhibitory pseudo kinase domain, JH3-5 contains the SH2 receptor interaction domains, and JH6-7 contains the FERM domain [12]. In the most basic paradigm, ligand-receptor interaction modifies the shape of receptor-JAK complexes, permitting the phosphorylation of certain tyrosine residues in JH1. This causes additional conformational shifts in JAK proteins, resulting in receptor phosphorylation and the creation of STAT protein binding sites [13].

The JAK/STAT signaling system can be triggered by external stimuli, for instance, cytokines. JAK and STAT are intracellular proteins that work with the transmembrane receptor to deliver signals to the nucleus, allowing DNA transcription and gene expression to occur [14]. STAT acts as a JAK substrate, phosphorylating and transporting to the nucleus to stimulate gene transcription.

The JAK/STAT signaling system is involved in stem cell maintenance, hematopoiesis, and the immune response [15].

CHAPTER 7**Transcription Factors in Cancer****Rawiah A. Alsiary^{1*}, Talat Abdullah Albukhari² and Waheed A. Filimban³**¹ King Abdullah International Medical Research Center (KAIMRC), WR King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), P.O. Box 9515, Jeddah, Saudi Arabia² Haematology and Immunology Department, Faculty of Medicine, Um Al Qura University, Makkah, Saudi Arabia³ Pathology Department, Faculty of Medicine, Um Al Qura University, Makkah, Saudi Arabia

Abstract: Different types of signalling pathways have been approved to be involved in cancer imitation and progression. These signalling pathways include the JAK-STAT signalling, NF- κ B signalling, Wnt, Notch and Hedgehog. STAT (Signal Transducer and Activator of Transcription) transports signals between proteins from the cell membrane into the nucleus to contribute to cancer progression. NF- κ B signalling is essential for the survival of the B cell tumor types. The Wnt, Notch, and Hedgehog signalling pathways play a significant role in carcinogenesis by upregulating the genes associated with these pathways. Hence, pharmacological inhibitors of WNT, NOTCH, and HH pathways are required in clinical studies. Such inhibitors have features that make them important during the clinical trial since they offer great potential as novel therapeutics for cancer. They also have an antitumor response which should be taken into consideration. The three signalling pathways are also known to shape cell fate determination and differentiation. In case of depletion of a single molecular component within the three pathways, embryonic lethality will form.

Keywords: HH signalling pathways, Hedgehog, NF- κ B, NOTCH, Signaling, STAT, Transcription, Wnt (β)-Catenin.

TRANSCRIPTION FACTORS IN CANCER

A transcription factor is a sequence-based DNA-binding protein that regulates the transcription of genetic material from DNA to messenger RNA *via* binding to specific DNA sequences in molecular biology and genetics. There are three types of transcription factors that are believed to play a role in human cancer.

* **Corresponding author Rawiah A. Alsiary:** King Abdullah International Medical Research Center (KAIMRC), WR King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), P.O. Box 9515, Jeddah, Saudi Arabia; E-mail: alsiaryra@ngha.med.sa

1- Steroid receptors, such as oestrogen receptors and androgen receptors, in breast cancer and prostate cancer, respectively. Anti-oestrogen and anti-androgen agents have been in clinical use for several years, such as tamoxifen and bicalutamide. Activated glucocorticoids have also been extensively used due to their ability to promote apoptosis, at least in lymphoid cells [1].

2- Resident nuclear proteins, which are activated by serine kinase cascades, are also transcription factors linked to cancer [2]. For example, JUN was identified as an oncogene in 1987, first as the viral Jun (v-Jun), then as the cellular Jun (c-Jun), and then as a transcription factor shortly after.

3- Latent cytoplasmic factor is the third and most recently identified group of transcription factors with oncogenic potential, whose function is usually activated by receptor-ligand interaction at the cell surface [2]. These transcription factors are triggered by serine or tyrosine kinases at the cell surface, or by a variety of cytoplasmic biochemical events that include kinases (some of which are regulated by Ca^{2+} flux) or precisely controlled proteolysis.

After synthesis, several transcription factors reach the nucleus spontaneously [2]. The bZip proteins include JUNB, c-JUN, c-FOS, JUND, ATFs, FRA, and the CREB-CREM family, the ETS proteins, the cEBP family, and the MAD box family, are among the main classes of structurally related proteins. In mammals, these classes comprise at least several hundred different proteins, only a few of which have been widely considered [3]. A general picture of the activities that regulate the resident nuclear-transcription factors' maximal transcriptional activity has arisen. While no JUN mutations have been identified in human cancers, upstream activators of JUN3 have been identified in a large number of mutations.

There are a variety of resident nuclear transcription factors that are overexpressed or presented as hyperactive fusion proteins in cancers. MYC, which is widely enhanced in cancer, is the most common of all [4]. MYC does not govern transcription by itself; instead, it forms a dimer with another protein called MAX [5]. E2F proteins are usually free in the tumor due to the common lack of RB. E2F is required for cell-cycle development, according to studies in cultured cells, though depletion of E2F prevents S-phase entry the most [6]. E2F dysfunction has been documented in cancer, despite the fact that most cancers have normal levels of E2F protein production. E2F level was significantly higher in 90% of small-cell lung cancer patients, but not in adenocarcinoma or squamous-cell lung carcinoma [7].

Signal Transducer and Activator of Transcription (STAT)

Definition

“STAT (Signal Transducer and Activator of Transcription) factors are proteins that have the ability to transduce signals from the cell membrane into the nucleus, thus activating gene transcription” [8, 9].

Types of STATs

In the human genome, up till now, seven kinds of STAT genes have been discovered, and they are as follows; “STAT1 chromosomal location 2q32.2, STAT2 12q13.3, STAT3 17q21.2, STAT4 2q32.), STAT5a 17q21.), STAT5b 17q21.2, STAT6 12q13.3” [8, 9].

Their signal transduction is included in numerous usual physiological cell procedures, counting propagation, variation, angiogenesis apoptosis and immune ruling. Irregularities may occur in its pathways, leading to abnormal STAT rules, which in turn lead to various pathological events, such as malicious alteration and “metastasis” of cells [10].

Features of the STAT Group of Proteins

All of the “STAT proteins” are made up of a quantity of functionally and as well as structurally preserved areas [11].

1. The “Src-homology 2 SH2” field, along with the “N-terminal domain ND” intercedes homo- and “heterodimerization” of STAT monomers throughout stimulation.
2. The “coiled-coil domain CCD” works as a signal of the nuclear locale by incriminating interactions between protein-protein.
3. The C-terminal “transcriptional activation domain TAD”, endures “serine phosphorylation” and thus employs extra activators that are transcriptional, improving the actions of STAT pertaining to transcriptions.
4. The “DNA-binding domain DBD” is responsible for the determination of DNA association [12, 13].

Some of the STAT proteins institute isoforms by alternate mRNA interweaving or processing of “post-translational proteolytic”. The isoforms that are of complete length are labelled “ α isoforms”, while their corresponding items that are full-length are termed “ β , γ or δ ” [13].

Epigenetic and Genetics Factors

Abeer A. Alsofyani^{1,*} and Yazan Samih Said²

¹ King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia

² King Fahad Specialist Hospital, Dammam, Saudi Arabia

Abstract: Despite variations in the morphology and behaviors of human body cells, every single cell in our body is composed of identical DNA material. The variation in cell phenotypes is a result of a specific regulatory mechanism known as epigenetics, by which gene expression undergoes some modifications without the actual nucleotide sequence being affected [1]. This phenomenon is accomplished through several mechanisms, such as cytosine residue methylation, modifications of histone units, and RNA interference. Therefore, epigenetics performs a key function in embryonic growth and development, cellular RNA expression, gene imprinting, and silencing of females' X chromosomes [2]. Any impairment in these mechanisms may cause various human disorders, including cancer [3]. In carcinogenesis, defective epigenetic machinery at several distinct levels results in abnormal cellular functions [4].

This chapter highlights epigenetics' importance in cancer development and its potential applications for cancer treatment.

Keywords: Cancer, Epigenetics, Histone, Methylation, miRNA.

MOLECULAR MACHINERY FOR METHYLATING DNA

DNA methylation is a central epigenetic process occurring in DNA, as it regulates gene expression and cell differentiation without altering nucleotide sequences [5, 6]. DNA methylation changes dynamically as cells develop, but the process becomes static as they begin to differentiate. This distinctive regulatory modification is indispensable for proper development, managing the expression of particular genes in specific tissues, allowing a cell to terminate DNA transcription, silencing one of the X chromosomes, and facilitating genomic imprinting.

* **Corresponding author Abeer A. Alsofyani:** King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia; E-mail: alsofyaniab@gmail.com

Normally, methylation occurs primarily in regions where cytosine-guanine dinucleotide repeats are highly condensed, also known as CpG islands [7]. Throughout our genome, CpG sites are not randomly distributed, and most cytosine residues are methylated. Around 70% of promoters contain these clusters, which are unmethylated to keep euchromatic conformation and allow transcription factors to bind in order to initiate gene expression [5, 8]. The methylation machinery is propelled by the DNA methyltransferase (DNMT) family [2]. This enzyme family used SAM as a group donor to add the CH₃ group to cytosine [9]. DNMTs are classified into three major types: DNMT1, DNMT2, and DNMT3. The latter has three sub-members: DNMT3A, DNMT3B, and DNMT3L [2]. DNMT1 is a maintenance enzyme that has a high affinity toward the hemimethylated region in the DNA helix. During cell division, the methylating activity of DNMT1 mimics the methylation process that takes place prior to DNA replication by binding to a newly synthesized DNA. Further, The DNMT1 protein also helps to restore DNA methylation [10].

In contrast to other members, DNMT2 shows no enzyme activity, and its role in DNA methylation is still largely unknown; however, it appears to be involved in methylating the amino acid tRNA cytosine. A DNMT3 enzyme family is usually involved in *de novo* methylation. *De novo* methylation occurs during gametogenesis through both DNMT3A and DNMT3B. In the case of DNMT3L, it is involved in the *de novo* methylating regulatory factor in extraembryonic tissue [11].

These covalent modifications can be removed at distinct development levels from the DNA helix through a mechanism called DNA demethylation. TET enzymes catalyze the conversion of 5-methylcytosine to 5-hydroxymethylcytosine using oxygen atoms to demethylate DNA [12, 13]. There are two types of demethylations: active and passive. Active DNA demethylation is an enzyme-driven process that demethylates methylated cytosine residues by removing the methyl group from these residues. Passive DNA demethylation takes place during successive stages of replication, leading to the loss of 5-methylcytosine [12].

MOLECULAR MACHINERY FOR HISTONE MODIFICATION

Acetylation of Lysine

Histone lysine (K) undergoes acetylation\ deacetylation through the involvement of two antagonistic enzymes; acetyltransferases (HATs) and deacetylases (HDACs) [14]. HATs allocate acetyl groups to the side chains of lysine by using acetyl CoA as a cofactor. In turn, it promotes DNA liberation by diminishing positive charges on lysine residues, consequently enhancing its approachability to

transcription factors and RNA polymerase complexes [15, 16]. There are three main groups of HATs: p300/CBP, MYST (which includes MOZ, MOF, TIP60, HBO1), and GNAT (which includes GCN5, PCAF) [17]. There are many cytoplasmic acetyltransferases, including MCM3AP, ARD1 and TFIIB, which can also acetylate-free histones and newly synthesized histones [18]. Moreover, acetyltransferases are capable of acetylating many non-histone proteins, allowing them to regulate the DNA binding, protein stability, and enzymatic functions [19].

Conversely, HDACs stop the histone acetylation process by restoring the lysine residue's positive charge and creating a closed chromatin conformation, allowing stabilization of the chromatin structure and controlling the gene silencing [15]. Human HDACs have four major classes [16, 20]. Together, these classes promote the closure of chromatin and the repression of gene expression. Moreover, as part of epigenetic modifications, HDAC removes acetyl groups from many non-histone proteins [21]. As transcriptional corepressors, HDACs typically form various functional complexes with other class members. HDAC1 and HDAC2 are usually present together within three distinct complexes NURD, Sin3a, and CoREST complexes. It has been shown that the purified forms of HDAC1 and HDAC2 exhibit weak deacetylation activity [22]. HDAC3 increases its activity by forming complexes with the SMRT and NCoR. Moreover, HDAC1, HDAC2, HDAC4, HDAC5, and HDAC7 deacetylases interact with NCoR without forming a complex [23 - 25]. Therefore, existing HDAC members made it difficult to distinguish which activity is responsible for a specific action. Thus, inhibitors targeting HDACs activity are now being developed as potential cancer therapy.

Methylation of Histone

During both the differentiation and development process, histone methylation occurs in a reversible and dynamic manner. As opposed to acetylation, methylation leaves the charge unchanged on lysine and arginine residues [15]. Gene activity can be induced or inhibited by methylating histones. For instance, a methyl group can inhibit gene expression at H4K20, H3K9, and H3K27, while methylating lysine at H3K79, H3K36, and H3K4 can activate gene expression [26].

Methylation of Lysine

Six major classes of histone lysine methyltransferase (HKMTs) can methylate the N-terminal lysine. Aside from KMT4, all HKMTs possess an equivalent SET motif that is necessary for enzymatic catalysis [15, 27, 28]. These enzymes catalyze methyl transfer to amino groups on the side chains of lysine using SAM

SUBJECT INDEX

A

Acid 132, 137, 146, 150, 191
 fumaric 150
 glutamic 146
 hydrochlorous 132
 lactic 150
 lysophosphatidic 191
 malic 150
 pyruvic 137
 Acquired immune deficiency syndrome 64
 Activity 38, 72, 101, 112, 252, 276, 326
 antineoplastic 72
 anti-tumor 252
 anti-tumorigenic 101
 carcinogenic 252
 catalytic 38
 cyclosome 112
 methyltransferase 326
 tyrosine kinase 276
 Acute lymphoblastic leukaemia 297
 Adenocarcinoma 23, 116, 126, 144, 147, 149,
 263, 274
 gastric 126, 144
 pancreatic 149
 pancreatic ductal 23
 Alzheimer's disease 68, 125
 Anaplastic lymphocyte kinase (ALK) 219
 Angiogenesis 6, 27, 28, 29, 30, 31, 63, 91, 93,
 131, 207, 208, 209, 210, 211, 213, 259,
 290
 cancer cell 259
 genetic instability 63
 neoplastic 290
 Antigenic tumor peptides (ATP) 130, 135,
 137, 138, 139, 146, 147, 341
 Antigen-presenting cells (APCs) 42, 109, 130,
 206, 295, 333
 Antioxidant glutathione 141
 Apoptosis 19, 40, 283
 independent cell death process 19
 inducing factor (AIF) 40

suppress 283
 Apoptotic pathways 63, 134, 147
 Ataxia telangiectasia mutated (ATM) 117,
 118, 123, 143
 Atherosclerosis 68

B

Barrett's adenocarcinoma 15
 Barr virus infection 126
 Basal cell nevus syndrome 300
 Bladder cancer 25, 58, 69, 126, 331, 340, 341
 Bone 31, 193, 215, 262, 296
 marrow-derived cells 31
 morphogenetic proteins (BMPs) 193, 215,
 262, 296
 Brain-derived neurotrophic factor (BDNF)
 216
 BRCA-associated cancers 123
 Breast cancer 68, 71, 123, 197, 215, 217, 254,
 258, 333, 334, 335, 336, 337, 340, 341,
 342
 metastatic 197
 Breast carcinomas 5, 69, 146, 147
 Burkitt lymphoma 53, 339

C

Cancer 8, 15, 17, 18, 22, 28, 56, 61, 62, 64,
 117, 123, 125, 126, 140, 146, 203, 212,
 214, 215, 217, 229, 248, 259, 280, 290,
 329, 330, 331, 332, 335, 337, 341
 angiogenesis 28
 cervical 56, 62, 64, 126, 333, 335, 336, 341
 esophageal 17, 331
 gallbladder 56
 gastrointestinal 215, 290
 glioma 18
 hematological 248, 337
 humanoid 280
 kidney 22
 lymphoid 259

Faris Q.B. Alenzi (Ed.)

All rights reserved-© 2023 Bentham Science Publishers

- malignant 15
 - metastatic 125, 203
 - myeloid 331
 - neck 64, 214, 215, 217
 - oral 8, 56, 123, 212
 - ovary 123
 - periodic 117
 - renal 140, 332, 339
 - stomach 61
 - testicular 331
 - thyroid 146
 - Candida albicans* 101
 - Canonical NF- κ B pathway 288
 - Carcinomas 16, 18, 42, 58, 88, 89, 131, 132, 139, 140, 141, 146, 214, 215, 251, 335
 - epithelial 215
 - esophageal 132, 335
 - gastric 140
 - gastrointestinal 16
 - renal cell 18, 42, 140, 141
 - Chemokines, tumor-promoting 128
 - Chlamydia psittaci* 55, 56
 - Chronic 26, 54, 127, 245, 248, 291, 300
 - lung diseases 54
 - lymphocytic leukemia (CLL) 26, 245, 248, 291
 - obstructive pulmonary disease (COPD) 127, 300
 - Cockayne's syndrome 121
 - Colorectal cancer 21, 25, 37, 54, 56, 58, 295, 299, 332, 334, 335, 336, 341
 - Crohn's disease 23, 127, 132
 - Cushing's syndrome 5
 - Cyclin-dependent kinase (CDK) 35, 37, 38, 112
 - Cytotoxic T lymphocytes (CTLs) 99, 100, 101, 108, 203, 205
- D**
- Deficiency 8, 20, 39, 108, 145, 332
 - nutritional 20
 - Dendritic cell (DCs) 27, 43, 98, 130, 134, 196, 258, 281, 288
 - Diffuse large B-cell lymphoma (DLBCL) 297, 334
 - Diseases 39, 53, 68, 125, 254
 - autoimmune 39
 - cardiovascular 125, 254
 - infectious 53
 - kidney 68
 - Disorders 3, 18, 27, 109, 115, 123, 195, 207, 254, 279, 343
 - autosomal recessive 123
 - immunological 254
 - myeloproliferative 279, 343
 - neoplastic 3
 - DNA 35, 112, 113, 115, 120, 121, 195, 320, 321, 328, 329, 330, 331, 332, 333, 334, 335, 341, 343
 - demethylation 321, 331
 - ligase 121
 - methylation 195, 320, 321, 329, 330, 331, 332, 333, 334, 335, 341, 343
 - replication 35, 112, 113, 115, 120
 - DNA damage 36, 38, 55, 59, 111, 113, 117, 118, 120, 121, 131, 132, 142, 143
 - repair 142, 143
 - Donnai-Barrow syndrome 300
 - Downstream, protein kinases 248
 - Dysregulation 38, 39, 93, 150, 192, 194, 243, 250, 297, 345
 - target epigenetic 345
 - transcriptional 192
 - transmembrane protein 194
- E**
- Endocytosis 188, 279, 284
 - Entamoeba histolytica* 60
 - Epidermal growth factor (EGF) 29, 33, 59, 99, 131, 188, 190, 191, 197, 212, 213, 214, 217, 219, 253, 254, 259, 260, 291
 - receptors (EGFR) 59, 213, 214, 217, 219, 253, 254, 259, 260
 - Epstein-Barr virus (EBV) 52, 53, 61, 259
 - Erythropoiesis 209
 - Escherichia coli* 55, 56

Subject Index

Extracellularly regulated kinases (ERKs) 14, 216, 248, 249, 250

F

Fanconi anemia (FA) 123, 144
Fibroblast 33, 103, 190, 191, 192, 204, 208, 210, 212, 214, 276
 activation protein (FAP) 103, 192
 growth factor (FGF) 33, 190, 191, 204, 208, 210, 212, 214, 276

G

Gene 115, 125, 324
 mutation 115, 125
 transcription regulation 324
Genetic mutations 27, 65, 131, 148, 194, 201, 204, 242
Glutaminolysis 146
Glycolysis 86, 136, 137, 138, 139, 140, 142, 146, 149, 150, 292

H

Hajdu-Cheney syndrome (HCS) 297
HBV infection 63
Heat shock proteins (HSPs) 108
Helicobacter pylori 55, 56, 125, 126
Hepatitis 61, 63, 258
 B virus (HBV) 61, 63, 258
 C virus (HCV) 61, 63
Hepatocellular 63, 126, 144, 245, 263, 295, 332, 335, 342
 cancer 334
 carcinoma 63, 126, 144, 245, 263, 295, 332, 335, 342
Hepatocyte growth factor (HGF) 33, 105, 131, 212, 214
Hexosamine biosynthesis pathway (HBP) 149
Hodgkin's lymphoma 61

Molecular Targets and Cancer Therapeutics (Part 1) 369

I

Immunity 14, 18, 20, 22, 23, 100, 130, 205, 244, 257
 adaptive 130, 257
 innate 130, 257
Immunodeficiency 259, 279, 280
Immunogenicity 129
Immunotherapy 27, 43, 204, 282, 283
 anti-telomerase 27, 43
Infections 54, 58, 63, 126
 chronic 63
 chronic HBV 63
 mansonii 58
 microbial 54, 126
Inflammatory bowel disease (IBD) 127, 132
Influence nucleosome interactions 325
Inhibitors, proteasome 30

J

JAK/STAT 243, 244, 245
 pathway 243, 245
 signaling pathway 243, 244
Joubert syndrome 300
Juvenile polyposis syndrome (JPS) 17

K

Kaposi sarcoma (KS) 64
Keratinocytes 101
Ketogenesis 137
Krebs cycle and gluconeogenesis 144

L

Lactate dehydrogenase 136, 139
Leukemia 30, 280, 338
 chronic myeloid 30
 granular lymphocytic 280
 lymphoblastic 338
 myeloid 336
Leukemic stem cells (LSCs) 89

Leukocytes 18, 99, 101, 125, 129, 196, 200
 tumor-promoting 101
 Lipolysis 137
Listeria monocytogenes 56
 Liver 25, 34, 59, 63, 67, 91, 127, 221, 243,
 251, 335, 336, 341
 cancer 25, 63, 221, 335, 336, 341
 cirrhotic 34
 steatosis 67
 Lung(s) 7, 54, 56, 68, 109, 115, 116, 127, 128,
 139, 146, 259, 334, 335, 338, 340
 cancer (LC) 7, 56, 109, 115, 116, 127, 128,
 334, 335, 338, 340
 carcinomas 54, 146
 epidermoid carcinoma 139
 inflammation 68
 malignancies 259
 Lymphangiogenesis 213
 Lymph node metastasis 144, 334
 Lymphoid organogenesis 288
 Lymphomas 8, 9, 15, 52, 57, 64, 71, 88, 89,
 280, 281
 Lynch syndrome 115

M

Malignancies 14, 15, 19, 20, 39, 43, 60, 90,
 91, 117, 118, 141, 207, 208, 246, 247,
 254, 258, 262
 aggressive 60
 colorectal 246
 hematologic 39
 nervous system 246
 prostatic 141
 Meckel 65, 119, 300
 syndrome 300
 cell carcinoma (MCC) 65, 119
 Metastasis-associated macrophages (MAMs)
 199
 Metastatic cancer disease 202
 Mitogen-activated protein kinase (MAPK) 32,
 70, 112, 133, 149, 189, 215, 242, 248,
 249
 Multiple myeloma 30, 258, 281, 293, 336

Myelodysplastic syndromes 251
 Myeloid-derived suppressor cells (MDSCs)
 23, 98, 102, 130, 213, 281
 Myeloperoxidase enzyme 66

N

Nasopharyngeal carcinoma(s) 126, 332, 334
 Natural 41, 44, 45, 130, 192, 280
 killer (NK) 41, 44, 45, 130, 280
 morphogenetic processes 192
 Neck carcinomas 16
 Necroptosis 12, 22, 23, 24
 encouraging 24
 inflammatory pathway-induced 22
 Neoangiogenesis 128, 189, 192
 Neoplasms 4, 5, 87, 88, 94, 104, 280, 297,
 334, 339
 endothelial cell 94
 hematological 334
 malignant 4, 5
 myeloid 280
 Nerve growth factor (NGF) 216
 NFB involving kinase (NIK) 257, 289
 Nitric oxide synthase 66, 99, 208
 Non-Hodgkin's lymphoma (NHL) 55
 Non-small cell lung cancer (NSCLCs) 42,
 116, 217, 219, 263

O

Oxidative 20, 25, 27, 58, 59, 68, 69, 141, 142,
 143
 species reduction 25
 stress 20, 27, 58, 59, 68, 69, 141, 142, 143
 Oxygen 29, 208
 hemostasis 208
 sensitive enzyme 29

P

Pancreatic 23, 34, 123, 206, 243, 335, 336,
 340

Subject Index

cancer 34, 123, 206, 243, 335, 336, 340
ductal adenocarcinoma (PDA) 23
Parkinson's disease 68
Pathways 149, 279
transaminase 149
ubiquitin-proteasome 279
Placenta growth factor (PIGF) 29, 209
Plasmodium falciparum 60
Platelet-derived growth factor (PDGF) 95, 97,
103, 104, 191, 207, 212, 254, 276, 291
Programmed cell death (PCD) 19, 22, 38, 41,
44, 45, 113, 118, 204, 205, 258, 261
Proliferating cell nuclear antigen (PCNA) 121
Proteases 40, 102, 192, 196, 202, 215, 247
cysteine cathepsin 102
Proteasomal degradation 260
Protein tyrosine phosphatases (PTPs) 69, 279
Proteolysis 38
Proteolytic enzymes 28, 32, 192, 208
Psoriasis 23, 101, 127

R

Ras 118, 251, 333
oncogenes 251
signaling 118, 251, 333
Receptor tyrosine kinases (RTKs) 220, 249,
250
Renal cell carcinoma (RCC) 18, 42, 140, 141
Replication stress 20
Resistance-associated secretory phenotype
(RASP) 109
Response 24, 130
mediated-immune 130
pro-inflammatory 24
Reverse transcriptase 24
RNA 61, 65, 68, 112, 135, 259, 273, 283, 320,
329
antisense 283
induced silencing 283
interference 320
messenger 273, 329
noncoding 329
tumor virus infections 259

Molecular Targets and Cancer Therapeutics (Part 1) 371

S

Salmonella typhi 55, 56
Signal transducer and activator of
transcription (STAT) 132, 133, 189, 244,
245, 273, 275, 276, 277, 279, 282
Simpson-Golabi-Behmel overgrowth
syndrome 300
Single nucleotide polymorphisms (SNPs) 147
Skin cancers 65, 114, 121
Smith-Lemli-Opitz syndrome (SLOS) 300
Smo protein 299
Sprouting 211
angiogenesis 211
tumour vasculature 211
Squamous cell cancer (SCC) 70, 144
Stress 19, 23, 43, 59, 66, 118, 147
mental 66
metabolic 19, 23, 43
Suppression, immune 131
Suppressor cells, myeloid-derived 23, 98, 102,
130, 213
Synthesis 23, 67, 111, 112, 120, 135, 138,
140, 141, 144, 145, 148, 150, 208, 274,
278
inflammatory cytokine 23
lipid 144, 145
macromolecule 135, 138, 150
nucleic acid 141

T

Target Ras proteins 252
Telomerase activity 24, 25
Therapies, anti-angiogenic 211
Thyroid carcinoma 300
TNF-induced 23, 259
apoptosis 23, 259
signaling 23
Toxoplasma gondii 60
Transforming growth factor (TGF) 15, 17, 28,
131, 132, 190, 191, 193, 194, 212, 215,
242, 261, 262
Tropomyosin receptor kinase (TRK) 220

- Tumor 23, 31, 33, 90, 91, 92, 93, 94, 127, 134, 143, 210
 - angiogenesis 31, 90, 93, 94, 134, 143, 210
 - apoptosis 23
 - carcinoma 127
 - endothelial cells (TECs) 33, 91, 92
- Tumor-associated 33, 98, 99, 102, 103, 130, 131, 216
 - dendritic cells (TADCs) 130
 - fibroblasts (TAFs) 103
 - macrophages (TAMs) 33, 98, 99, 102, 130, 131, 216
- Tumor cell 44, 125, 146, 258
 - proliferation 44, 125, 146
 - propagation 258
- Tumor necrosis 22, 24, 29, 38, 98, 101, 132, 205, 258, 278
 - factor (TNF) 23, 24, 29, 98, 101, 205, 258, 278
- Tyrosine kinase receptors (TKRs) 212, 213, 215, 216, 218, 278

U

- Urothelial carcinoma (UC) 42

V

- Vascular 28, 29, 30, 93, 94, 99, 131, 133, 143, 191, 199, 209, 210, 212, 213, 218
 - endothelial growth factor (VEGF) 28, 29, 30, 93, 94, 99, 133, 143, 191, 199, 209, 210, 212, 213, 218
 - permeability factor (VPF) 131, 209

W

- White blood cells (WBCs) 91, 132
- Whole-genome sequencing 339



Faris Q.B. Alenzi

Prof. Faris Alenzi received his MSc and PhD from Imperial College London in 2003. Prof. Faris is a passionate educator and researcher in allergy, immunology and cancer. Prof. Faris's interests go further than teaching as he is keen on serving his community through his community work. He is the founder of multiple charities including: The Saudi Society for Allergy, Asthma and Immunology, Saudi Society for Cell Death, Moafa Health Charity, Roya Fekrya Charity. He is also an editor and publisher for five Arabic books. Prof. Faris is a recipient of the British Journal of Hematology Award & the Leukemia Research Fund Award, London, UK. He obtained many research grants in total ~2M USD. In March 2019, he was among the Professional Achievement Award Finalists. In October 2022, he was selected among The Stanford University top 2% researchers in the world.